Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

John Patrick Curtin

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-OB/GYN CHAIR GENERAL OPS

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Pothuri B, Curtin JP. In memoriam: Franco M Muggia. Int J Gynecol Cancer. 2022 Apr 04; 32(4):580. PMID: 35058333.
      View in: PubMed
    2. Palmere L, Guido J, Schultz C, Curtin J, Muffly TM. Nonresearch Payments by Industry to Obstetrics and Gynecology Fellowship Directors. Obstet Gynecol. 2021 12 01; 138(6):894-896. PMID: 34736274.
      View in: PubMed
    3. Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV. Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression. Gynecol Oncol. 2020 04; 157(1):280-286. PMID: 32057464.
      View in: PubMed
    4. Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, Curtin JP, Pothuri B. Neoadjuvant chemotherapy in patients with advanced endometrial cancer. Cancer Chemother Pharmacol. 2019 08; 84(2):281-285. PMID: 30980132.
      View in: PubMed
    5. Cadena I, Werth VP, Levine P, Yang A, Downey A, Curtin J, Muggia F. Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis. Ecancermedicalscience. 2018; 12:837. PMID: 29910834.
      View in: PubMed
    6. Lee J, Curtin JP, Muggia FM, Pothuri B, Boyd LR, Blank SV. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer. Cancer Chemother Pharmacol. 2018 07; 82(1):55-63. PMID: 29704010.
      View in: PubMed
    7. Lee J, Gerber D, Aphinyanaphongs Y, Curtin JP, Boyd LR. Laparoscopy decreases the disparity in postoperative complications between black and white women after hysterectomy for endometrial cancer. Gynecol Oncol. 2018 04; 149(1):22-27. PMID: 29605045.
      View in: PubMed
    8. Schwartz ZP, Frey MK, Philips S, Curtin JP. Endometrial cancer surveillance adherence reduces utilization and subsequent costs. Gynecol Oncol. 2017 09; 146(3):514-518. PMID: 28734496.
      View in: PubMed
    9. Frey MK, Sandler G, Sobolev R, Kim SH, Chambers R, Bassett RY, Martineau J, Sapra KJ, Boyd L, Curtin JP, Pothuri B, Blank SV. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes. Gynecol Oncol. 2017 07; 146(1):123-128. PMID: 28495237.
      View in: PubMed
    10. Frey MK, Blank SV, Curtin JP. Minimizing Minimally Invasive Surgery for Endometrial Carcinoma. Am Soc Clin Oncol Educ Book. 2017; 37:23-28. PMID: 28561642.
      View in: PubMed
    11. Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2017 Feb; 144(2):279-284. PMID: 27931751.
      View in: PubMed
    12. Lee J, Aphinyanaphongs Y, Curtin JP, Chern JY, Frey MK, Boyd LR. The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer. Gynecol Oncol. 2016 09; 142(3):508-13. PMID: 27288543.
      View in: PubMed
    13. Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 07; 15(7):1557-67. PMID: 27196780.
      View in: PubMed
    14. Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap? Cancer. 2016 Mar 15; 122(6):859-67. PMID: 26938270.
      View in: PubMed
    15. Momtahen S, Curtin J, Mittal K. Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma. J Clin Med Res. 2016 Mar; 8(3):181-9. PMID: 26858789.
      View in: PubMed
    16. Chern JY, Curtin JP. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. Curr Treat Options Oncol. 2016 Jan; 17(1):1. PMID: 26714493.
      View in: PubMed
    17. Shin SM, Duckworth TL, Cooper BT, Curtin JP, Schiff PB, DeWyngaert JK, Lymberis SC. Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer. Front Oncol. 2015; 5:201. PMID: 26442213.
      View in: PubMed
    18. David-West G, Musa F, Frey MK, Boyd L, Pothuri B, Curtin JP, Blank SV. Cross-Sectional Study of the Impact of a Natural Disaster on the Delivery of Gynecologic Oncology Care. Disaster Med Public Health Prep. 2015 Dec; 9(6):605-8. PMID: 26155945.
      View in: PubMed
    19. Hsu HC, Li X, Curtin JP, Goldberg JD, Schiff PB. Surveillance epidemiology and end results analysis demonstrates improvement in overall survival for cervical cancer patients treated in the era of concurrent chemoradiotherapy. Front Oncol. 2015; 5:81. PMID: 25918687.
      View in: PubMed
    20. Zechmeister JR, Pua TL, Boyd LR, Blank SV, Curtin JP, Pothuri B. A prospective comparison of postoperative pain and quality of life in robotic assisted vs conventional laparoscopic gynecologic surgery. Am J Obstet Gynecol. 2015 Feb; 212(2):194.e1-7. PMID: 25108142.
      View in: PubMed
    21. Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. Gynecol Oncol. 2014 Feb; 132(2):468-73. PMID: 24316308.
      View in: PubMed
    22. Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer. 2013 Nov; 23(9):1577-82. PMID: 24172094.
      View in: PubMed
    23. Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Ann Surg Oncol. 2014 May; 21(5):1468-73. PMID: 24081797.
      View in: PubMed
    24. Cooke J, Carew S, Quinn C, O'Connor M, Curtin J, O'Connor C, Saunders J, Humphreys E, Deburca S, Clinch D, Lyons D. The prevalence and pathological correlates of orthostatic hypotension and its subtypes when measured using beat-to-beat technology in a sample of older adults living in the community. Age Ageing. 2013 Nov; 42(6):709-14. PMID: 23934598.
      View in: PubMed
    25. Sethi RA, Jozsef G, Grew D, Marciscano A, Pennell R, Babcock M, McCarthy A, Curtin J, Schiff PB. Is there a role for an external beam boost in cervical cancer radiotherapy? Front Oncol. 2013; 3:3. PMID: 23386995.
      View in: PubMed
    26. Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist. 2012; 17(12):1534-40. PMID: 22622146.
      View in: PubMed
    27. Korets SB, Curtin JP. Surgical options for recurrent uterine sarcomas. Am Soc Clin Oncol Educ Book. 2012; 362-6. PMID: 24451764.
      View in: PubMed
    28. Bartels PH, Garcia FA, Trimble CL, Kauderer J, Curtin J, Lim PC, Hess LM, Silverberg S, Zaino RJ, Yozwiak M, Bartels HG, Alberts DS. Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):129-35. PMID: 22155796.
      View in: PubMed
    29. Korets SB, Czok S, Blank SV, Curtin JP, Schneider RJ. Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res. 2011 Dec 15; 17(24):7518-28. PMID: 22142830.
      View in: PubMed
    30. Novetsky AP, Boyd LR, Curtin JP. Trends in bilateral oophorectomy at the time of hysterectomy for benign disease. Obstet Gynecol. 2011 Dec; 118(6):1280-1286. PMID: 22105256.
      View in: PubMed
    31. Nair N, Curtin JP, Mittal K, Hiotis KL. Cervical adenocarcinoma in a patient with Lynch syndrome, Muir-Torre variant. J Clin Oncol. 2012 Jan 10; 30(2):e5-6. PMID: 22124091.
      View in: PubMed
    32. Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L, Muggia F. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011 Oct; 10(10):2000-7. PMID: 21835933.
      View in: PubMed
    33. Muggia F, Cannon T, Safra T, Curtin J. Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer. J Natl Cancer Inst. 2011 Jan 19; 103(2):160-1. PMID: 21115880.
      View in: PubMed
    34. Andreopoulou E, Chen T, Liebes L, Curtin J, Blank S, Wallach R, Hochster H, Muggia F. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer Chemother Pharmacol. 2011 Aug; 68(2):457-63. PMID: 21069334.
      View in: PubMed
    35. Boyd LR, Novetsky AP, Curtin JP. Ovarian cancer care for the underserved: are surgical patterns of care different in a public hospital setting? Cancer. 2011 Feb 15; 117(4):777-83. PMID: 20922804.
      View in: PubMed
    36. Boyd LR, Novetsky AP, Curtin JP. Effect of surgical volume on route of hysterectomy and short-term morbidity. Obstet Gynecol. 2010 Oct; 116(4):909-915. PMID: 20859155.
      View in: PubMed
    37. Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol. 2010 Dec; 119(3):451-6. PMID: 20837357.
      View in: PubMed
    38. Safra T, Andreopoulou E, Levinson B, Borgato L, Pothuri B, Blank S, Tiersten A, Boyd L, Curtin J, Muggia F. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. Anticancer Res. 2010 Sep; 30(9):3243-7. PMID: 20944093.
      View in: PubMed
    39. Whyte JS, Gurney EP, Curtin JP, Blank SV. Lymph node dissection in the surgical management of atypical endometrial hyperplasia. Am J Obstet Gynecol. 2010 Feb; 202(2):176.e1-4. PMID: 20022313.
      View in: PubMed
    40. Mittal K, Sebenik M, Irwin C, Yan Z, Popiolek D, Curtin J, Palazzo J. Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy. Mod Pathol. 2009 Jan; 22(1):37-42. PMID: 19116629.
      View in: PubMed
    41. Blank SV, Curtin JP. More than a name. J Clin Oncol. 2007 Aug 10; 25(23):3551; author reply 3557-8. PMID: 17687163.
      View in: PubMed
    42. Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, Jacobs A, Curtin J, Muggia F. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007 Apr; 18(4):716-21. PMID: 17301073.
      View in: PubMed
    43. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, Gallup DG. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15; 106(4):804-11. PMID: 16400640.
      View in: PubMed
    44. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15; 106(4):812-9. PMID: 16400639.
      View in: PubMed
    45. Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5912-9. PMID: 16115933.
      View in: PubMed
    46. Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Aug; 94(2):368-74. PMID: 15297174.
      View in: PubMed
    47. Lu MJ, Sorich J, Hazarika M, Kim M, Del Priore G, Jacobs AJ, Chiang C, Liu PC, Fusco E, Curtin JP, Muggia FM. Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. Hematol Oncol Clin North Am. 2003 Aug; 17(4):969-75. PMID: 12959186.
      View in: PubMed
    48. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol. 2003 Jun; 30(3):401-12. PMID: 12870142.
      View in: PubMed
    49. Hines BJ, Porges RF, Mittal K, Muggia FM, Curtin JP. Use of medroxyprogesterone acetate in the treatment of M?llerian adenosarcoma: a case report. Gynecol Oncol. 2002 Apr; 85(1):192-5. PMID: 11925144.
      View in: PubMed
    50. Harlap S, Olson SH, Curtin JP, Caputo TA, Nakraseive C, Sanchez D, Xue X. Epithelial ovarian carcinoma and fertility of parents. Epidemiology. 2002 Jan; 13(1):59-65. PMID: 11805587.
      View in: PubMed
    Curtin's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (258) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)